(CercleFinance.com) – UBS downgrades its recommendation on Roche from ‘neutral’ to ‘sell’, with a price target maintained at 345 Swiss francs, a target which therefore implies an estimated downside potential of 12% for the title of the pharmaceutical group Swiss.
‘SKYSCRAPER-01 does not reflect a free upside option and is highly dependent on gantenerumab in Alzheimer’s’, the broker believes in its note summary, adding that ‘Phase IIIs may be asking the wrong questions’ .
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
